Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma
These findings support the use of circulating protein signatures as minimally invasive, scalable biomarkers to inform early treatment decisions in the neoadjuvant setting.
Authors
- Fengtang Yang (ORCID: https://orcid.org/0000-0002-3573-2354)
- Jean Yang (ORCID: https://orcid.org/0000-0002-5271-2603)
- Jordan W. Conway (ORCID: https://orcid.org/0000-0003-1161-9119)
- Su Yin Lim (ORCID: https://orcid.org/0000-0001-9576-5441)
- Inês Pires da Silva (ORCID: https://orcid.org/0000-0003-3540-8906)
- Helen Rizos (ORCID: https://orcid.org/0000-0002-2094-9198)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Lijia Yu (ORCID: https://orcid.org/0000-0001-6735-9569)
- Alexander M Menzies
Institutions
- The University of Sydney (AU)
- Royal North Shore Hospital (AU)
- Blacktown & Mount Druitt Hospital (AU)
- Melanoma Institute Australia (AU)
- Macquarie University (AU)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1186/s12935-025-04067-4
- Citations
- 1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- U.S. Department of Defense
- Cancer Institute NSW
- Macquarie University
- Melanoma Institute Australia
- Medical Research Council
- National Health and Medical Research Council